All Stories

  1. Extracellular Endothelial Cell-Derived Vesicles: Emerging Role in Cardiac and Vascular Remodeling in Heart Failure
  2. Altered adipocytokine profile predicts early stage of left ventricular remodeling in hypertensive patients with type 2 diabetes mellitus
  3. Diagnostic and therapeutic value of micro-RNAs in inflammatory bowel disease
  4. Efficacy of fixed dose of triple combination of perindopril-indapamide-amlodipine in obese patients with moderate-to-severe arterial hypertension: an open-label 6-month study
  5. P6603The predictive role of T786C single nucleotide polymorphism in endothelial no-synthase gene in late left ventricular remodeling after ST-segment elevation myocardial infarction
  6. Impaired function of fibroblast growth factor 23 / Klotho protein axis in prediabetes and diabetes mellitus: Promising predictor of cardiovascular risk
  7. Circulating platelet-derived vesicle in atrial fibrillation
  8. Altered signature of apoptotic endothelial cell-derived microvesicles predicts chronic heart failure phenotypes
  9. Platelet-derived vesicles: diagnostic and predictive value in cardiovascular diseases
  10. Platelet-Derived Vesicles in Hypertension: New Target for Risk Stratification?
  11. Vascular Access Surgery - Tips and Tricks
  12. Circulating vascular endothelial growth factor in ST-segment elevation myocardial infarction: from bench to bedside
  13. Prognostication of clinical outcomes in diabetes mellitus: Emerging role of cardiac biomarkers
  14. Dynamic changes of circulating vascular endothelial growth factor levels in ST-segment elevation myocardial infarction: Controversies in clinical interpretation
  15. Endothelial progenitor cell dysfunction in diabetes mellitus: new target for risk stratification and therapies?
  16. Cellular care and extracellular vesicles therapies of heart failure
  17. Elevated levels of circulating soluble ST2 at discharge predict late adverse ventricular remodeling in patients with ST-segment elevation myocardial infarction
  18. The endothelial progenitor cell dysfunction in hypertension: the diagnostic and predictive values
  19. Association of growth-differentiation factor-15 with the number of circulating proangiogenic endothelial progenitor cells in patients with type 2 diabetes mellitus
  20. Neutrophil extracellular traps: The core player in vascular complications of diabetes mellitus
  21. Emerging Role of Galectin-3 in Pulmonary Artery Hypertension
  22. Reply to: Is serum uric acid a pretty accurate prognostic predictor of ST elevated acute coronary syndrome? Author: Alexander E. Berezin
  23. Circulating biomarkers in heart failure: diagnostic and prognostic importance
  24. Stem Cells and Stem Cells / Precursors-Derived Extracellular Vesicles in Heart Failure: What is Better for Cardiac Regeneration?
  25. Is serum uric acid a pretty accurate prognostic predictor of ST elevated acute coronary syndrome?
  26. Effect of Thymol against Fungi Deteriorating Mural Paintings at Tell Basta Tombs, Lower Egypt
  27. Circulating Biomarkers in Heart Failure
  28. The role of progenitor endothelial cell dysfunction in arterial hypertension
  29. Can C-reactive Protein Genetic Variants Identify Patients with Higher and Lower Cardiovascular Risk?
  30. Is Galectin-3 a Prognosticator of Severity and Clinical Outcomes of Pulmonary Artery Hypertension?
  31. The endothelial progenitor cell dysfunction in type 2 diabetes mellitus: the link with heart failure developing
  32. The Endothelial Progenitor Cell Dysfunction in Type 2 Diabetes Mellitus: The Link with Heart Failure Developing
  33. Progenitor Endothelial Cells in Pulmonary Arterial Hypertension
  34. Challenging role of neutrophil extracellular traps in vascular complications of diabetes mellitus
  35. The Impact of Endothelial Progenitor Cell Dysfunction in Heart Failure “Obesity Paradox”
  36. The Impact of Endothelial Progenitor Cell Dysfunction in Heart Failure “Obesity Paradox”
  37. The obesity phenotypes: emerging role of cardiac biomarkers
  38. Promising utilities of growth differentiation factor 15 in cardiovascular diseases
  39. Growth Differentiation Factor 15 As Promising Biomarker Of Poor Prognosis In Heart Failure
  40. Pattern of Micro Vesicles in Heart Failure: Novel Biomarker of Endothelial Dysfunction and Vascular Reparation
  41. Enterococcus faecium L-3 in Eradication of Helicobacter pylori: In-vivo and In-vitro
  42. Serum uric acid as a metabolic regulator of endothelial function in heart failure
  43. [BP.04.06] CIRCULATING ENDOTHELIAL-DERIVED APOPTOTIC MICROPARTICLES TO MONONUCLEAR PROGENITOR CELLS RATIO AS A PREDICTOR OF THROMBOEMBOLIC EVENTS IN PATIENTS WITH ACUTELY DECOMPENSATED HEART
  44. Dysfunction of Endothelial Cell Precursors in Heart Failure Development
  45. Uric Acid in Heart Failure: Controversy Factor in The Multiple Pathogenesis of The Disease
  46. P6493Non-classical phenotypes of circulating endothelial cell-derived progenitor cells predicts asymptomatic atherosclerosis metabolically unhealthy obesity
  47. Up-to-date clinical approaches of biomarkers’ use in heart failure
  48. 1314Endothelial progenitor cells and apoptotic endothelial cell-derived microparticle ratio predicts atrial fibrillation in chronic heart failure
  49. Abstracts
  50. Are inflammatory cytokines and angiogenic factors a predictive biomarker of diabetes retinopathy?
  51. The Controversial Role of Osteopontin in Vascular Calcification: From Bench to Bedside
  52. Abstract Book: ISEV2017
  53. Biosensing of Circulating Apoptotic Endothelial Cell Micro particles: The Impact in Risk Stratification of Obesity
  54. Circulating apoptotic endothelial cell-derived microparticles are predicted metabolically unhealthy obesity
  55. Assessment of nephroprotective action of angiotensin-converting enzyme inhibitor ramipril in patients with chronic glomerulonephritis
  56. Biosensing of periprocedural events in acute ST-segment elevation myocardial infarction patients with the erythrocyte-derived microparticles
  57. "Obesity Paradox" in Heart Failure: The Possible Role of Progenitor Endothelial Cell Dysfunction
  58. Microparticles in Chronic Heart Failure
  59. The predictive value of circulating apoptotic endothelial cell-derived micro particles in obesity progression?
  60. Number of Circulating Endothelial Progenitor Cells as a Predictive Biomarker of Heart Failure
  61. The Growth/Differentiation Factor-15 in Chronic Heart Failure: New Challenge in Biomarker-Guided Therapy?
  62. The Role of Vistafin in Diabetes-Induced Impairment of Endothelial Repair System
  63. The role of circulating endothelial progenitor cell dysfunction in pregnancy-induced hypertension
  64. Preconditioned Endothelial Progenitor Cells as Biomarker of Vascular Reparation?
  65. Novel Biomarkers in Prediction of Heart Failure Related Outcomes: From Bench to Bedside
  66. Current understanding of the role of new cardiac biomarkers in prediction of heart failure
  67. The placental cell-derived exosomes as a promising predictive biomarker of preeclampsia in symptomatic pregnancies
  68. Hypertension in Pregnancy: The Role of Circulating Endothelial Progenitor Cell Dysfunction
  69. Are Placental Cell-Derived Exosomes a Predictive Biomarker of Preeclampsia?
  70. Are Novel Cardiac Biomarkers Required in Prediction of Heart Failure Development and Outcomes?
  71. Could be Used an Immune Phenotypes of Circulating Endothelial Progenitor Cells as a Biomarker of Cardiovascular Disease?
  72. The Advanced Bright-field Light Optical Polarization Microscopy: Novel Coupling Method for Detection of Micro Vesicles
  73. Growth-Differentiation Factor-15 as Additional Prognostic Biomarkers in Heart Failure
  74. The Controversial Role of Serum Uric Acid in Cardiovascular Diseases
  75. The Endothelial Progenitor Cell Dysfunction: The Missed Predictor of Heart Failure Outcomes?
  76. Novel Biomarkers for Cardiovascular Risk in Obese Patients
  77. Combined methods for micro particles determining: are they useful?
  78. Osteopontin in Vascular Calcification: A Central Player or Accidental Witness?
  79. Coupling Analytical Methods for Detection of Microparticles: The Possibilities for Improvement
  80. Preconditioned Endothelial Progenitor Cells as Biomarker of Vascular Reparation?
  81. Progenitor Cell Dysfunction: The Role of Endothelial Precursors in Heart Failure
  82. Epigenetics in heart failure phenotypes
  83. Cardiac biomarkers in diabetes mellitus: New dawn for risk stratification?
  84. An association of serum vistafin level and number of circulating endothelial progenitor cells in type 2 diabetes mellitus patients
  85. Acute Cardiovascular Care 2016
  86. Biomarkers for cardiovascular risk in patients with diabetes: Table 1
  87. Links Between Concentrations of Serum 25-hydroxyvitamin D3 and the Numbers of Circulating Progenitor Mononuclear Cells in Patients With Metabolic Syndrome
  88. Endothelial progenitor cells dysfunction and impaired tissue reparation: The missed link in diabetes mellitus development
  89. Is rationale to decrease serum osteoprotegerin and fetuin-A in type 2 diabetes mellitus patients?
  90. Poster session 2Morphogenetic mechanisms290MiR-133 regulates retinoic acid pathway during early cardiac chamber specification291Bmp2 regulates atrial differentiation through miR-130 during early heart looping formationDevelopmental genetics294Associati...
  91. Data regarding association between serum osteoprotegerin level, numerous of circulating endothelial- derived and mononuclear-derived progenitor cells in patients with metabolic syndrome
  92. PS105 Impaired Immune Phenotype of Circulating Endothelial-Derived Microparticles in None-Diabetic Patients with Chronic Heart Failure
  93. Is the neutrophil extracellular trap-driven microvascular inflammation essential for diabetes vasculopathy?
  94. Abstracts
  95. Metabolic memory phenomenon in diabetes mellitus: Achieving and perspectives
  96. EuroHeartCare 2016
  97. Relation of osteoprotegerin level and numerous of circulating progenitor mononuclears in patients with metabolic syndrome
  98. Pattern of endothelial progenitor cells and apoptotic endothelial cell-derived microparticles in chronic heart failure patients with preserved and reduced left ventricular ejection fraction
  99. Circulating thrombospondin-2 in patients with moderate-to-severe chronic heart failure due to coronary artery disease
  100. The pattern of circulating microparticles in patients with diabetes mellitus with asymptomatic atherosclerosis
  101. The Neutrophil Extracellular Traps: The Missed Link between Microvascular Inflammation and Diabetes?
  102. Pattern of circulating endothelial-derived microparticles among chronic heart failure patients with dysmetabolic comorbidities: The impact of subclinical hypothyroidism
  103. Impaired Immune Phenotype of Endothelial Cell-derived Micro Particles: The Missing Link between Diabetes-related States and Risk of Cardiovascular Complications?
  104. The Role of Circulating Myeloid-Related Protein Complex Calprotectin in Prediction of Heart Failure with Preserved Ejection Fraction
  105. The Rationality to Use of Galectin-3 as Target in Biomarker-Guided Therapy of Type 2 Diabetes Mellitus
  106. The Biomarker Utility in Risk Stratification in an Ambulatory Heart Failure: ST2 or Galectin-3?
  107. Prognostication in Different Heart Failure Phenotypes: The Role of Circulating Biomarkers
  108. Aortic Stenosis: Predictive Value of Cardiac Biomarkers in Older Patients
  109. Does Visfatin Predict Cardiovascular Complications in Metabolic Syndrome Patients?
  110. Extracellular vesicles as novel delivery drug system in heart failure: from bench to bedside?
  111. Elevated galectin-3 level predicts pulmonary artery hypertension
  112. Molecular and biochemical mechanisms of mitochondrial dysfunction in spontaneously hypertensive rats
  113. Predictive value of vistafin in metabolic syndrome patients: focus on cardiovascular complications
  114. Single sample and serial measurements of osteoprotegerin level as a target of therapy in type 2 diabetes mellitus?
  115. Circulating endothelial-derived apoptotic microparticles and insulin resistance in non-diabetic patients with chronic heart failure
  116. Determination of early tumoricidal drug-induced cardiotoxicity with biological markers
  117. Can Osteoprotegerin be a Target of Therapy in Type 2 Diabetes Mellitus?
  118. Non-Classical Progenitor Mononuclears in Metabolic Syndrome: The Role of Serum 25-Hydroxyvitamin D3
  119. Impaired Pattern of Endothelial Cell-Derived Microparticles in Heart Failure Patients with Preserved and Reduced Left Ventricular Ejection Fraction
  120. Progenitor Endothelial Cell Dysfunction in Heart Failure: Clinical Implication and Therapeutic Target?
  121. Utilization of Novel Delivery Drug Systems Based on Release of Extracellular Vesicles in Heart Failure
  122. Global Longitudinal Strain and Strain Rate in Type Two Diabetes Patients with Chronic Heart Failure: Relevance to Osteoprotegerin
  123. Genetic Predictive Scores in Heart Failure: Possibilities and Expectations
  124. Progenitor Endothelial Cell Dysfunction in Obese Patients: Possibilities for Cardiovascular Risk Prediction
  125. Altered endothelial reparation and diabetes-Induced endothelial progenitor cell dysfunction
  126. Are Epigenetic Features Essential in Advance of Heart Failure Phenotypes?
  127. Blood pressure measurement assistance and antihypertensive drug compliance in older patients
  128. Circulating Vascular Endothelial Growth Factor-1 in Cardiovascular Disease
  129. Endothelial Repair in Diabetes: The Causative Role of Progenitor Cells Dysfunction?
  130. Epigenetic Mechanisms of Endothelial Progenitor Cell Dysfunction
  131. Epigenetic Modifications the Development of Different Heart Failure Phenotypes
  132. Epigenetically Modified Endothelial Progenitor Cells in Heart Failure
  133. Is Elevated Circulating Galectin-3 Level A Predictor of Pulmonary Artery Hypertension Development and Progression?
  134. Serum cystatin C and neutrophil gelatinase-associated lipocalin as biomarkers of glomerular and tubular kidney damage in patients with chronic glomerulonephritis and saved renal function
  135. Serum interleukin-18 as a biomarker of tubular kidney damage in patients with chronic glomerulonephritis
  136. The Cell-Free Mitochondrial DNA: A Novel Biomarker of Cardiovascular Risk?
  137. The Clinical Utility of Circulating Microparticles’ Measurement in Heart Failure Patients
  138. Endothelial Progenitor Cell Dysfunction as a Biomarker of Cardiovascular Risk in Obese Patients
  139. Different Obese Phenotypes and Progenitor Endothelial Cell Dysfunction: The Missed Link to Cardiovascular Risk
  140. Utility of the Red Blood Cell-Derived Microparticles as a Marker of Periprocedural Adverse Effects amongst Patients with Acute ST-Segment Elevation Myocardial Infarction
  141. The Endothelial Cell Secretome as a Factor of Endothelium Reparation: The Role of Microparticles
  142. The Promises, Methodological Discrepancies and Pitfalls in Measurement of Cell-Derived Extracellular Vesicles in Diseases
  143. The approaches to none-invasive detection of cell-derived extracellular vesicles
  144. The heart failure risk predictive scores based on the genetic features: hope and hype
  145. The risk stratification in heart failure patients: The controversial role of high-sensitive ST2
  146. The signature of circulating microparticles in heart failure patients with metabolic syndrome
  147. Biomarker-Guided Therapy for Chronic Heart Failure
  148. Endothelial progenitor cell-mediated vascular repair system in diabetes
  149. Pattern of circulating microparticles in chronic heart failure patients with metabolic syndrome: Relevance to neurohumoral and inflammatory activation
  150. Predictive value of circulating osteonectin in patients with ischemic symptomatic chronic heart failure
  151. Novel biomerker-based score for heart failure
  152. Predictive Value of Circulatingve-catherin in Coronary Artery Disease Patients with Symptomatic Moderate to Severe Chronic Heart Failure
  153. Stable Coronary Artery Disease Patients: Different Practice Patterns in Everyday Clinical Situations
  154. Endothelial Derived Micro Particles: Biomarkers for Heart Failure Diagnosis and Management
  155. Diabetes mellitus related biomarker: The predictive role of growth-differentiation factor-15
  156. Impaired phenotype of circulating endothelial microparticles in chronic heart failure patients: Relevance to body mass index
  157. The effect of angiotensin-2 receptor blocker valsartan on circulating level of endothelial progenitor cells in diabetic patients with asymptomatic coronary artery disease
  158. The Association of Subclinical Hypothyroidism and Pattern of Circulating Endothelial-Derived Microparticles Among Chronic Heart Failure Patients
  159. The Impact of Low-Grading Inflammation on Circulating Endothelial-Derived Progenitor Cells in Patients with Metabolic Syndrome and Diabetes Mellitus
  160. Impaired Immune Phenotype of Circulating Endothelial-Derived Microparticles in None-Diabetic Patients with Chronic Heart Failure: Impact on Insulin Resistance
  161. The predictive role of circulating microparticles in patients with chronic heart failure
  162. Predictive role of circulating endothelial-derived microparticles in cardiovascular diseases
  163. [PP.36.09]
  164. [PP.36.08]
  165. Moderated Poster Session 2: Sunday 3 May 2015, 15:30-16:30 * Room: Moderated Poster Area
  166. Poster Session 2: Monday 4 May 2015, 08:00-18:00 * Room: Poster Area
  167. Poster Session 3: Tuesday 5 May 2015, 08:30-12:30 * Room: Poster Area
  168. Predictive value of apoptotic microparticles to mononuclear progenitor cells ratio in advanced chronic heart failure patients
  169. Impaired immune phenotype of circulating endothelial-derived microparticles in patients with metabolic syndrome and diabetes mellitus
  170. Rational Synthesis of AB-Type N -Substituted Core-Functionalized Naphthalene Diimides (cNDIs)
  171. Содержание циркулирующих эндотелиальных прогениторных клеток у пациентов с хронической сердечной недостаточностью ишемической природы с сохраненной фракцией выброса левого желудочка
  172. Circulating Vascular Endothelial Growth Factor-1 in Cardiovascular Disease
  173. The association of serum osteoprotegerin/ sRANKL complex, C-reactive protein and adiponectin with number of circulating endothelial progenitor cells in patients with metabolic syndrome and diabetes mellitus
  174. The Role of Cardiac Biomarkers in Predicting of Mortality in Diabetic Patients
  175. The Development of Biological Molecular Sensing Techniques to detect Micro particles: Focus on Clinical Medicine Benefits
  176. Complications of Pharmacological Spasm Provocation Tests
  177. The Interplay of Aging, Aortic Stiffness and Blood Viscosity in Atherogenesis
  178. Transluminal endovascular aortic repair and pregnancy: a case report
  179. Inflammatory phenotype of circulating endothelial-derived microparticles in chronic heart failure patients with metabolic syndrome
  180. Micro RNA as Biomarkers and Tool for Target-Based Treatment in Patients with Inflammatory Bowel Diseases
  181. Immune Phenotypes of Endothelial-Derived Microparticles in Dysmetabolic Patients.
  182. Immune Phenotype of Circulating Endothelial-derived Microparticlesin Elderly Patients with Metabolic Syndrome and Diabetes Mellitus
  183. Vascular Endothelial Growth Factor-1 Level and Functional Neurologic Recovery after Ischemic Hemispheric Stroke
  184. The Metabolic Effects of Mineralocorticoid Receptor Antagonists in Heart Failure Patients
  185. Prognostication of heart failure development and advance: the role of high-sensitive ST2
  186. Impaired Phenotype of Circulating Endothelial-Derived Microparticles: Novel Marker of Cardiovascular Risk
  187. Circulating Cell-Free Mitochondrial DNA as Biomarker of Cardiovascular risk: New Challenges of Old Findings
  188. Biomarker-Guided Therapy for Chronic Heart Failure
  189. Bone-Related Proteins as Markers in Vascular Remodeling
  190. Utility of Biomarkers in Contemporary Management of Chronic Heart Failure
  191. Cardiovascular Biomarkers in Routine Screening of Diabetic Pati ents
  192. Early tumoricidal drug-induced cardiotoxicity determination: possibilities of biological markers
  193. The Pattern of Circulating Microparticles in Diabetes Mellitus Patients with Known Subclinical Atherosclerosis
  194. Signature of circulating endothelial-derived progenitor cells in patients with metabolic syndrome and diabetes mellitus
  195. Cell therapy of chronic heart failure: perspective of clinical approach
  196. The fixed combination of aliskiren and nebivolol in hypertensive patients: the clinical perspectives
  197. Impact of age on pattern of circulating endothelial-derived microparticles in heart failure patients
  198. Predictive Value of Circulating SPARC-Related protein Osteonectin in Patients with Symptomatic Moderate-to-Severe Ischemic-Induced Chronic Heart Failure
  199. The relationship between serum uric acid level and concentration of proangiogenic mononuclear progenitor cells in patients with chronic heart failure
  200. Relationship between circulating endothelial progenitor cells and insulin resistance in non-diabetic patients with ischemic chronic heart failure
  201. P202Interrelationship between circulating osteoprotegerin and subclinical coronary atherosclerosis in patients with type two diabetes mellitus
  202. P194Serum uric acid as independent predictor of decreased number of circulating proangiogenic progenitor cells in asymptomatic coronary artery disease patients
  203. Circulating Endothelial Progenitor Cells as Markers for Severity of Ischemic Chronic Heart Failure
  204. Impaired Pattern of Endothelial Derived Microparticles in Heart Failure Patients
  205. Diabetes mellitus and cellular replacement therapy: Expected clinical potential and perspectives
  206. Serum Uric Acid Predicts Declining of Circulating Proangiogenic Mononuclear Progenitor Cells in Chronic Heart Failure Patients
  207. Serum Rankl/Osteoprotegerin Complex and Endothelial Progenitor Cells in Chronic Heart Failure
  208. Predictive Value of Circulating Vascular Endothelial Growth Factor-1 Level Measured Repeatedly During Long-Term Follow-Up in Patients with Arterial Hypertension after Acute Ischemic Stroke
  209. Predictive Value of Circulating Apoptotic Microparticles in Patients with Ischemic Symptomatic Moderate-To-Severe Chronic Heart Failure
  210. Apoptotic Microparticles as Predicted Biomarkers in Patients with Chronic Heart Failure – Relevance to Inflammatory Cytokines and Outcomes
  211. C-reactive protein after stroke in arterial hypertension
  212. Vascular endothelial growth factor-1 as a predictor of unfavorable cardiovascular events in arterial hypertension patients after ischemic stroke
  213. Relationship between level of circulating endothelial progenitor cells and severity of ischemic chronic heart failure with preserved left ventricular ejection fraction
  214. Predict value of circulating bone-related glycopeptide osteoprotegerin in asymptomatic coronary artery disease patients with second type diabetes mellitus
  215. Predict value of circulating endothelial progenitor cells in patients with moderate-to-severe chronic heart failure due to coronary artery disease
  216. Circulating osteopontin as a marker of early coronary vascular calcification in type two diabetes mellitus patients with known asymptomatic coronary artery disease
  217. Analysis of Various Subsets of Circulating Mononuclear Cells in Asymptomatic Coronary Artery Disease
  218. Oral Abstract Session: Novel non-invasive risk marker
  219. Prognostic value of biological markers in myocardial infarction patients
  220. Circulating endothelial progenitor cells as a predictor of clinical outcomes in diabetic patients with symptomatic chronic heart failure
  221. A potential predict value of circulating osteoprotegerin in diabetic patients with asymptomatic coronary artery disease
  222. Serum Uric Acid as a Marker of Coronary Calcification in Patients with Asymptomatic Coronary Artery Disease with Preserved Left Ventricular Pump Function
  223. Predictive Value of Circulating Vascular Endothelial Growth Factor-1 in Arterial Hypertension Patients
  224. Bone-related circulating proteins as early predictors of coronary atherosclerosis in asymptomatic patients with known coronary artery disease
  225. Neuroprotective and memory enhancing properties of a dual agonist of the FGF receptor and NCAM
  226. Poster session 1
  227. Poster session 3
  228. TRANSFORMING GROWTH FACTOR-BETA 1 AND HEART REMODELING IN TYPE 2 DIABETES MELLITUS PATIENTS ASSOCIATED WITH LEFT VENTRICULAR DIASTOLIC DYSFUNCTION
  229. SIMVASTATIN IN ESCALATION DOSES IMPROVE RENAL FUNCTION IN PATIENTS WITH DIABETES MELLITUS AND MILD-TO-MODERATE PROTEINURIA
  230. OSTEOPONTIN PLASMA LEVEL AS A TARGET IN THE ASSESSMENT OF SEVERITY HEART FAILURE AND CARDIAC REMODELLING
  231. CIRCULATING STROMELYSIN-1 AS A POSSIBLE MARKER OF SEVERITY OF CARDIOVASCULAR REMODELING IN OBESITY PATIENTS AFTER MYOCARDIAL INFARCTION
  232. Abstracts
  233. Abstracts
  234. Saturday, 17 July 2010
  235. Candesartan cilexitil reduces neurohumoral and proinflammatory activation in patients with severe congestive heart failure
  236. 774 Highly selective beta-1 blocker bisoprolol significantly improves long-term prognosis in asymptomatic heart failure patients
  237. 724 Low doses of statins improve neurohumoral activity in patients with moderate-to-severe congestive heart failure due to coronary artery disease
  238. 313 The interrelation between plasma level of natriuretic peptide and long-term prognosis about patients with congestive heart failure
  239. 166 Angiotensin-2 receptor blockade with losartan improves left ventricular function at rest and post-exercise in heart failure patients with preserved ejection fraction
  240. 470 Angiotensin-2 receptor blockade with losartan improves left ventricular function at rest and post-exercise in heart failure patients with preserved ejection fraction
  241. Losartan in the Therapy of Heart Failure Patients
  242. 4.11 The interrelation between plasma level of atrial natriuretic peptide and long-term prognosis about patients with congestive heart failure
  243. 4.10 Long-term administration of angiotensin-2 receptor antagonist losartan adding to ace inhibitor enalapril in patients with congestive heart failure
  244. The dose-dependent influence of angiotensin-II receptor antagonist losartan on remodeling and neurohumoral status in patients with congestive heart failure
  245. Angiotensin-II receptor antagonist losartan improves the diastolic performance in patients with asymptomatic heart failure due to myocardial infarction
  246. Biological Markers and Guided Therapy